2010
DOI: 10.1016/j.cytogfr.2010.02.006
|View full text |Cite
|
Sign up to set email alerts
|

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

Abstract: It is time for those working on oncolytic viruses to take stock of the status of the field. We now have at our disposal an array of potential therapeutic agents, and are beginning to conduct early-phase clinical trials in patients with relapsed/metastatic cancers. By drawing on lessons learned during the development of other biological therapies, such as monoclonal antibodies and targeted small molecule inhibitors, we are now in a position to chart the course of the next wave of trials that will go beyond the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
81
0

Year Published

2011
2011
2015
2015

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 87 publications
(82 citation statements)
references
References 41 publications
1
81
0
Order By: Relevance
“…However, it may be most effective when utilized in combination with conventional chemotherapy (Harrington et al, 2010). Recent studies have used cyclophosphamide, gemcitabine or cisplatin to improve the activity of Reolysin in solid tumors (Smakman et al, 2006;Qiao et al, 2008;Pandha et al, 2009;Sei et al, 2009).…”
Section: Discussionmentioning
confidence: 99%
“…However, it may be most effective when utilized in combination with conventional chemotherapy (Harrington et al, 2010). Recent studies have used cyclophosphamide, gemcitabine or cisplatin to improve the activity of Reolysin in solid tumors (Smakman et al, 2006;Qiao et al, 2008;Pandha et al, 2009;Sei et al, 2009).…”
Section: Discussionmentioning
confidence: 99%
“…This has led to numerous clinical studies as reviewed by others (Black and Morris, 2012;Clements et al, 2014;Harrington et al, 2010;Kelly et al, 2009;Maitra et al, 2012). Despite the fact that reoviruses are naturally oncolytic without prior genetic modifications, there is still a significant research effort ongoing to obtain novel virus variants better adapted to infect, replicate in, and kill cancer cells while sparing non-transformed cells (van den Hengel et al, 2013;Kim et al, 2011;Rudd and Lemay, 2005;Shmulevitz et al, 2012;van den Wollenberg et al, 2009van den Wollenberg et al, , 2012.…”
Section: Introductionmentioning
confidence: 99%
“…As excellently summarized by Harrington et al and Maitra et al, 137,143 these trials have shown safety with regards to toxicity of mORV-T3D administration to patients with various solid tumors without dose limiting toxicities, while having some appreciable anti-tumor effects in phase II/III trials.…”
Section: Family Poxviridae: Vaccinia Virus (Vv)mentioning
confidence: 91%
“…137,143 Limited mORV shedding has been observed in clinical trials in patient samples of urine, saliva and feces, mostly with high intravenous administrations. 137 As an RNA virus with a viral RNA polymerase, mORV genome replication is prone to errors which can lead to mutations in offspring.…”
Section: Family Poxviridae: Vaccinia Virus (Vv)mentioning
confidence: 99%